Loading…
Loading…
NAOV (NanoVibronix, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
NAOV does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NAOV and 80,000+ other tickers.
See exactly how NAOV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NAOV and 80,000+ other tickers.
NanoVibronix, Inc., operating through its subsidiary NanoVibronix Ltd., develops and commercializes innovative, non-invasive devices that stimulate biological responses for therapeutic purposes. Their core focus areas include mitigating biofilm formation, accelerating wound repair, and alleviating pain. Key among their product line is UroShield, an ultrasound-based solution engineered to deter bacterial colonization and biofilm development in urinary catheters, thereby boosting antibiotic efficacy and reducing associated patient discomfort. They also offer PainShield and WoundShield, both…
TYLER, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced it has completed the transition of its NanoVibronix manufacturing operations from Israel to the United States, and consolidated its research and development operations in Tel Aviv, Israel, supporting the Company's broader initiative to reduce operating expenses and improve its cost structure. “Completing the transition of our NanoVibronix product line manufacturing to the United States marks the achievement of a major strategic operational initiative for the Company,” said Doron Besser, MD, CEO of ENvue Medical.
Technology supports the evolution of enteral access from blind procedures to real-time visualized placement Technology supports the evolution of enteral access from blind procedures to real-time visualized placement
Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record of driving top-line growth Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record of driving top-line growth
The program will integrate the Company's clinically validated NanoVibronix technology to improve comfort associated with indwelling nasogastric tubes The program will integrate the Company's clinically validated NanoVibronix technology to improve comfort associated with indwelling nasogastric tubes
Peak Medical, ENvue's Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit Peak Medical, ENvue's Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit